Cargando…

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

BACKGROUND: Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Lars Henning, Kümmel, Andreas, Görlich, Dennis, Mohr, Michael, Bröckling, Sebastian, Mikesch, Jan Henrik, Grünewald, Inga, Marra, Alessandro, Schultheis, Anne M., Wardelmann, Eva, Müller-Tidow, Carsten, Spieker, Tilmann, Schliemann, Christoph, Berdel, Wolfgang E., Wiewrodt, Rainer, Hartmann, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552388/ https://www.ncbi.nlm.nih.gov/pubmed/26313362 http://dx.doi.org/10.1371/journal.pone.0136023

Ejemplares similares

Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
por: Brand, Caroline, et al.
Publicado: (2016)

Adjuvant chemotherapy—Radiotherapy—Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases
por: Schliemann, Christoph, et al.
Publicado: (2018)

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
por: Man, Johnathan, et al.
Publicado: (2021)

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
por: Brabetz, Oliver, et al.
Publicado: (2017)

Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision
por: Schmidt, Lars Henning, et al.
Publicado: (2016)

Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1(high) with CD8/PD-1(high)
por: Ma, Si-Rui, et al.
Publicado: (2023)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
por: Wu, Yanhua, et al.
Publicado: (2017)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer
por: Bulk, Etmar, et al.
Publicado: (2012)

Regulators of Actin Dynamics in Gastrointestinal Tract Tumors
por: Steinestel, Konrad, et al.
Publicado: (2015)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13—Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease
por: Gerwing, Mirjam, et al.
Publicado: (2021)

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth
por: Bäumer, Nicole, et al.
Publicado: (2018)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
por: Stucke-Ring, Janine, et al.
Publicado: (2016)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8hmcjnsoams2llpribt2s4ok9f